학술논문
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: Results from the phase 2 CheckMate 9KD trial
Document Type
Article
Author
Fizazi, K.; Retz, M.; Petrylak, D.P.; Goh, J.C.; Perez-Gracia, J.; Lacombe, L.; Zschäbitz, S.; Burotto, M.; Mahammedi, H.; Gravis, G.; Bastos, D.A.; McCune, S.L.; Limón, J.C.V.; Kwan, E.M.; Castellano, D.; Fléchon, A.; Saad, F.; Grimm, M.-O.; Shaffer, D.R.; Armstrong, A.J.; Bhagavatheeswaran, P.; Amin, N.P.; Ünsal-Kaçmaz, K.; Wang, X.; Li, J.; Loehr, A.; Pachynski, R.K.
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 17 August 2022, 10(8))
Subject
Language
English
ISSN
20511426